A Case Report Capecitabine-Induce Grade II Hand and Foot Syndrome
DOI:
Abstract Views:
33 times
PDF Downloads:
14 times
Abstract
Abstract—Capecitabine has a common side effect of hand and foot syndrome (HFS). It is cutaneous capecitabine’s adverse effect, which generally occurs within 11 to 360 days. In this case report assesses the delayed onset of capecitabine because HFS did not occur within 11-360 days but rather took longer, specifically 720 days. A female patient of 82 years old with a history of breast cancer was diagnosed four years ago. She did not undergo radiation and surgery, only capecitabine tablets as neoadjuvant therapy since April 2021. In August 2023, the patient complained of pain, dryness, and blood in both legs. Analysis of side effects of the drug was carried out using the Naranjo Probability Scale. Therapy management during hospitalization involves stopping capecitabine and performing wound care by applying fusidic acid cream and the patient's complaints improved on the eleventh day of therapy. Capecitabine discontinuation is the most effective strategy to minimize the effect of HFS. Further research is to determine the effectiveness of emollient application as a prevention for HFS.
Keywords: adverse effects, capecitabine, hand and foot syndrome
Abstrak—Sindrom tangan dan kaki efek samping yang sering terjadi pada penggunaan kapesitabine. Efek samping ini merupakan efek samping pada kulit yang terjadi dalam jangka waktu 11 hingga 360 hari. Pada case report ini efek samping tidak terjadi dalam jangka waktu 11-360 hari, terjadi keterlambatan reaksi yang berlangsung pada 720 hari setelah penggunaan kapesitabin. Seorang pasien perempuan berusia 82 tahun dengan riwayat kanker payudara didiagnosis empat tahun lalu. Pasien tidak menjalani radiasi dan operasi, hanya mengonsumsi tablet kapesitabin sebagai terapi neoadjuvan sejak April 2021. Pada Agustus 2023, pasien mengeluhkan nyeri, kulit kering, dan berdarah pada kedua kakinya. Analisis efek samping obat dilakukan dengan menggunakan Skala Probabilitas Naranjo. Penatalaksanaan terapi selama rawat inap meliputi penghentian kapesitabin dan perawatan luka dengan krim asam fusidat dan keluhan pasien membaik di hari ke-11 terapi. Penghentian kapesitabin merupakan strategi yang paling efektif untuk meminimalkan efek HFS. Penelitian selanjutnya adalah untuk menentukan efektivitas pemberian emolien sebagai pencegahan HFS.
Kata kunci: efek samping, kapesitabin, sindrom kaki dan tangan
Downloads
References
Vardanian R, & Hruby V. Antineoplastic Agents. Academic Press; 2016.
Aguado C, García-Paredes B, Sotelo MJ, Sastre J, Díaz-Rubio E. Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? World J Gastroenterol. 2014;28;20(20):6092-101. Available from: https://doi.org/ 10.3748/wjg.v20.i20.6092
Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol. 2005;16(8):1289-96. Available from: https://doi.org/10.1093/annonc/mdi253.
Varshavsky-Yanovsky AN, Goldstein LJ. Role of Capecitabine in Early Breast Cancer. J Clin Oncol. 2020;38(3):179-182 Available from: https://doi.org /10.1200/JCO.19.02946.
Inokuchi M, Ishikawa S, Furukawa H, Takamura H, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Ohta T. Treatment of capecitabine-induced hand-foot syndrome using a topical retinoid: A case report. Oncol Lett. 2014;7(2):444-448. Available from: https://doi.org/10.3892/ol.2013.1706.
de Queiroz MVR, de Medeiros ACTR, Toledo SP, de Abreu Sarmenghi KD, de Vasconcellos VF. Hand-foot syndrome caused by capecitabine: incidence, risk factors and the role of dermatological evaluation. Ecancermedicalscience. 2022;16;16:1390. Available from: https://doi.org/10.3332/ecancer.2022.1390
Liang G, Ma W, Zhao Y, Liu E, Shan X, Ma W, Tang D, Li L, Niu X, Zhao W, Zhang Q. Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters. BMC Cancer. 2021;7;21(1):362. Available from: https://doi.org/10.1186/s12885-021-08028-8
Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, Zeng S. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome. Chem Res Toxicol. 2016;29(10):1591-1601. Available from: https://doi.org/10.1021/acs.chemrestox.6b00215.
Braghiroli CS, Ieiri R., Ocanha JP, Paschoalini RB, & Miot, HA. Do you know this syndrome? Hand-foot syndrome. Anais Brasileiros de Dermatologia. 2017;92(1):131–133. Available from: https://doi.org/10.1590/abd1806-4841.20174602
U.S. Department of Health and Human Services. [Internet]. Common Terminology Criteria for Adverse Events (CTCAE). [Cited 2024 Sept 10]. Available from: Cancer Therapy Evaluation Program (CTEP), ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
Schmulenson E, Krolop L, Simons S et al. Evaluation of patient-reported severity of hand–foot syndrome under capecitabine using a Markov modeling approach. Cancer Chemother Pharmacol. 2020;86:435–444. Available from: https://doi.org/10.1007/s00280-020-04128-7
Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev. 2020 May 13;14(1):442. Available from: https://doi.org/10.4081/oncol.2020.442.
Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, et al. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial. JAMA Oncol. 2017;3(11):1538-1545. Available from: https://doi.org/10.1001/jamaoncol.2017.1269.
Kwakman JJM, Simkens LHJ, van Rooijen JM, van de Wouw AJ, Ten Tije AJ, et al. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Ann Oncol. 2017;28(6):1288-1293. Available from: https://doi.org/10.1093/annonc/mdx122.
Mrozek-Orlowski ME, Frye DK, Sanborn HM. Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncology Nursing Forum. 1999;26(4):753-762.
Reichardt P, Von Minckwitz G, Thuss-Patience PC et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol. 2003;14: 1227-1233
Khan QJ. Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial. Journal of Clinical Oncology. 2023;41:1007-1007.Availablefrom:https://doi.org/ 10.1200/JCO.2023.41.16_suppl.1007
Ndoli DA, Manirakiza A, Rubagumya F. Capecitabine Induced Hand-Foot Syndrome-A Case report. Rwanda Medical Journal. 2020;77(3):6-8.
King TL, Voon PJ, Yuen KH, Mohamed Noor DA. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia. Support Care Cancer. 2024;32(6):345. Available from: https://doi.org/10.1007/s00520-024-08490-7
Reis FCGP, Menêses AG, Mazoni SR, Silveira RCCP, Reis PED, Vasques CI. Topical interventions for preventing hand-foot syndrome resulting from antineoplastictherapy: A scoping review. Rev Esc Enferm USP. 2023;57:e20230107. Available from: https://doi.org/10.1590/1980-220X-REEUSP-2023-0107en
Huang XZ, Chen Y, Chen WJ, Zhang X, Wu CC, Wang ZN, et al. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome: prevention strategies for capecitabine-induced HFS. Int J Cancer. 2018;142(12):2567–77. Available from: http://dx.doi.org/10.1002/ijc.31269
Kao YS, Lo CH, Tu YK, Hung CH. Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: a network meta-analysis of randomized control trials. Dermatol Ther (Heidelb). 2022;35(10):e15774. Available from: http://dx.doi.org/10.1111/dth.15774
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- Articles published in Keluwih: JKK are licensed under a Creative Commons Attribution-ShareAlike 4.0 International license. You are free to copy, transform, or redistribute articles for any lawful purpose in any medium, provided you give appropriate credit to the original author(s) and the journal, link to the license, indicate if changes were made, and redistribute any derivative work under the same license.
- Copyright on articles is retained by the respective author(s), without restrictions. A non-exclusive license is granted to Kluwih: JKK to publish the article and identify itself as its original publisher, along with the commercial right to include the article in a hardcopy issue for sale to libraries and individuals.
- By publishing in Keluwih: JKK, authors grant any third party the right to use their article to the extent provided by the Creative Commons Attribution-ShareAlike 4.0 International license.
